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Abstract
The development of a hybrid PET/CT led to the recognition of the enhanced glycolysis in brown fat. We report a
previously unrecognized mechanism for altered fluorodeoxyglucose (FDG) biodistribution with diffuse white
adipose tissue uptake. This occurred during a restaging scan for cervical cancer following administration of insulin
in the setting of measured hyperglycemia. The patient’s blood sugar normalized, but she experienced symptoms
and signs of hypoglycemia. A subsequent history indicated that the patient received intravenous high-dose vitamin
C just prior to arrival. Ascorbic acid is a strong reducing agent and can cause erroneous false positive portable
glucometer readings. Accordingly, it is likely the patient was euglycemic on arrival and was administered FDG
during a period of insulin-induced hypoglycemia. Prominent diffuse white adipose tissue, gastric mucosal,
myocardial, and very low hepatic and muscle activity were observed. The case provides insight into the metabolic
changes that occur during hypoglycemia and the potential danger of relying on portable glucometer readings. We
discuss the potential biological basis of this finding and provide recommendations on the avoidance of this
complication.
Background
The development of hybrid positron emission tomogra-
phy/computed tomography (PET/CT) devices led to the
recognition of enhanced glycolysis in brown fat, typically
in the neck and paravertebral regions of the thorax and
upper abdomen, as a thermoregulatory response and
under catecholamine stimulation [1-3]. Other atypical
patterns of fat uptake in patients with lipodystrophy
have been reported [2,3] We report a previously unrec-
ognized mechanism for altered fluorodeoxyglucose
(FDG) biodistribution into adipose tissues.
Case presentation
A 40-year-old woman presented for restaging with F-18
FDG PET/CT on the background of squamous cell car-
cinoma of the cervix and biopsy proven recurrence in a
left supraclavicular node. Conventional imaging had
demonstrated no further evidence of metastatic disease.
She had previously received radical chemoradiotherapy
for FIGO stage IIIb disease with para-aortic nodal invol-
vement, without intervening therapy in the 6 months
since completing the treatment. The patient was not
diabetic and had a body mass index of 24, which is in
the normal range for a female. She had no other past
medical history, took no medications, and had fasted
from the previous evening.
On arrival, her blood glucose level (BGL) obtained
with a portable glucometer (Abbott Diabetes Care
Optium Xceed, Alameda, CA, USA) via a fingerprick
capillary blood sample was 15 mmol/L, and she was
administered 6 U of short-acting insulin intravenously
as per local protocol. Thirty minutes later, her BGL had
fallen to 6.9 mmol/L, and she described feeling unwell
with anxiety, palpitations, and sweating. Her blood pres-
sure, temperature, and oxygen saturation levels were
normal, and she was observed. The BGL measurements
plateaued at 6.0 mmol/L, and FDG was subsequently
injected. PET/CT scanning was performed 60 min later.
The images demonstrated altered biodistribution of
FDG with a prominent uptake of the radiotracer
throughout white adipose tissue (WAT), gastric mucosa,
myocardium and very low hepatic activity (standardized
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tively) (Figure 1). WAT was most prominent in intra-
abdominal (mesenteric) fat. There was negligible muscle
uptake (SUVmax, 1.0).
Given this unusual biodistribution, we questioned the
patient further. She reported receiving an intravenous
infusion of high-dose vitamin C (sodium ascorbate solu-
tion) from another health practitioner just prior to her
arrival for the PET scan. Ascorbic acid is a strong redu-
cing agent and interferes with laboratory tests involving
oxidation and reduction reactions. Substantially reduced
or elevated portable glucometer readings occur with
ascorbic acid in a dose-dependent fashion and is one of
the most common interfering substances that affects the
accuracy of glucose meters [4,5]. A plasma venous sam-
ple was not available to confirm either plasma glucose
or ascorbic acid as blood was obtained via fingerprick,
and the error was not suspected prospectively. Never-
theless, the clinical symptoms of hypoglycemia and a
history of intravenous ascorbic acid just prior to arrival
at the PET scan, provides sufficient evidence to indicate
that the patient was injected with FDG during a period
of iatrogenic hypoglycemia induced by administration of
insulin in the setting of a falsely elevated BGL reading.
Based on the unusual pattern of uptake, the study was
repeated the following day in the absence of vitamin C.
BGL was normal on arrival, and the FDG biodistribution
was normal on the repeat study (see Figure 2; Addi-
tional file 1).
Discussion
This case highlights the potential limitations of standar-
dized insulin protocols [6,7], especially when relying on
point-of-care glucometers. Intravenous ascorbic acid
may result in substantial error in glucometer readings
[4,5]. This is of particular relevance for cancer imaging
as some complementary care practitioners advocate the
use of vitamin C in conjunction with chemotherapy or
radiotherapy in a wide variety of malignancies [8]; more-
over, many patients choose not to tell their doctors
about concomitant use of alternative medicines [9].
Clinicians should also be aware of other potential causes
of error resulting in factitious hyperglycemia including
substances containing maltose (e.g., intravenous human
immunoglobulin) [10], icodextrin (e.g., peritoneal dialy-
sis solution) [11] and galactose. Indeed, several deaths
have been reported, and warnings have been issued by
health regulatory agencies [12-15]. Accordingly, a
patient should be questioned regarding the use of not
only conventional chemotherapy and mediations but
also whether they are having alternative therapies.
The case also illustrates a remarkable pattern of pro-
minent WAT glycolytic activity on FDG PET. We
hypothesize that this was likely physiologic and in
Figure 1 Biodistribution of FDG. Coronal PET, PET/CT fusion, and CT images demonstrating prominent subcutaneous white adipose tissue
metabolic activity throughout the thorax, abdomen, and pelvis (arrows). More intense metabolic activity uptake was observed in intra-abdominal
fat (arrow). Intense gastric and myocardial uptake combined with low hepatic and negligible muscle uptake was observed.
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insulin. This is different than the characteristic pattern
of diffuse muscular uptake visualized in hyperinsuline-
mic patients, during hyperinsulinemic euglycemic
clamping or following oral glucose loading for optimiza-
tion of cardiac imaging [16], or in nonfasted or hyper-
glycemic patients undergoing oncologic imaging [6]. It
is also different than the pattern of FDG uptake
observed in brown fat adipose tissue in cervical, supra-
clavicular, paravertebral regions, mediastinal, and
suprarenal regions [1-3].
During hypoglycemia, major changes in metabolism
occur, including mobilization of liver glycogen and
release of energy stored in WAT into circulation as
nonesterified fatty acids. Our findings demonstrate rela-
tive high-glucose uptake into adipocytes in response to
hypoglycemia in a distribution consistent with WAT
activation. The two main defenses to hypoglycemia are
an increase in glucagon secretion and adrenaline secre-
tion [17]. Glucagon, secreted by pancreatic a-cells,
results in the stimulation of adenylate cyclase activity
within adipocytes and plays the primary role in counter
hormone regulation by promoting lipolysis in WAT
[18-20]. Lipolysis also occurs via adrenaline released
from the sympathetic nervous system terminals inner-
vating WAT [21]. Catecholamines also activate brown
fat with beta-blockers having been advocated as an
intervention to reduce this confounding finding on FDG
PET in predisposed individuals [22]. Other growth hor-
mones such as FGF-21 may also play role. FGF-21 has
been shown to stimulate glucose uptake in adipocytes
and suppress hepatic glucose production [23]. Elevated
FGF-21 levels have also been described in patients with
HIV-associated lipodystrophy [24], where atypical FDG
fat distribution is also described [25,26].
An additional hypothesis is that high-dose ascorbic
acid administered in a short time period prior to the
study is responsible, possibly in part, for the observed
increased WAT glycolytic activity. Ascorbic acid dietary
supplementation has been shown to reduce abdominal
and subcutaneous fat depots in high-fat diet-induced
adiposity animal models [27]. This study demonstrated
upregulation of genes involved in cell proliferation and
downregulation of genes participating in lipid
Figure 2 Results of repeated study on biodistribution of FDG. Coronal PET and PET/CT fusion images demonstrating normal distribution of
FDG in the study performed the following day when normoglycemic in the absence of prior ascorbic acid or exogenous insulin.
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with ascorbic acid.
At the sites of increased WAT metabolic activity, a
higher Hounsfield unit (HU) on CT was observed in the
same region of WAT compared to the study performed
one day later. Although not visually discernable, HU
averaged -71 within WAT compared to -86 on the sec-
ond scan, with an identical HU in other tissues such as
muscle. This phenomenon has been described in brown
adipose tissue (BAT) but, to the best of our knowledge,
has not been described before in WAT. A prior animal
and patient study demonstrated that the total lipid con-
tent of BAT was substantially decreased when activated
under cold conditions, with a corresponding increase in
CT HUs [28]. In this case, a rapid consumption of
stored lipid within WAT may also account for the
change seen. Greater blood flow in activated fat may
also contribute to the rise in HU [29].
Conclusion
FDG PET/CT is a useful noninvasive imaging modality
for visualizing metabolic changes within adipocytes.
A greater understanding of the role of both brown and
white adipocyte tissue as endocrine organs is of public
health interest as they may be central to our improved
understanding of obesity and diabetes mellitus [30]. The
mechanisms of observed WAT glycolytic activity in this
case study are proposed but uncertain. In particular, the
role of exogenous insulin, physiologic hormonal
responses to hypoglycemia or ascorbic acid in inducing
WAT glycolytic activity is uncertain. Further controlled
studies utilizing FDG and tracers that interrogate other
metabolic and receptor pathways may enhance our
understanding of endocrine pathophysiology.
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